An observational study in Ventricular Arrythmia, Cardiogenic Shock and Electrical Storm, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France — 2 open to participants now, 3 under way, 1 of them phase 3. Shock, Cardiogenic · Central Hospital, Nancy, France.
Among the 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 12th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →2 of the 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 58 across the 5 interventional studies, 300 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
1 of the studies in Shock, Cardiogenic by Central Hospital, Nancy, France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Electrical storm (ES) is a life-threatening syndrome defined by the recurrence of ventricular arrythmias.
ES is also represented by a wide spectrum of clinical situations ranging from recurrent monomorphic VT reduced by anti-tachycardia pacing (ATP) in relatively stable patients to recurrent VF in hemodynamically unstable patients.
Thus, the purpose of this study was to assess the incidence and predictors of long term mortality following hospitalization in the intensive care unit for ES, in a large retrospective multicentric study.
Electrical storm (ES) is a life-threatening syndrome defined by the recurrence of ventricular arrythmias) and commonly occurs in implantable cardioverter defibrillator (ICD) recipients with an incidence ranging from 10 to 58% for secondary prevention. ES is also represented by a wide spectrum of clinical situations ranging from recurrent monomorphic VT reduced by anti-tachycardia pacing (ATP) in relatively stable patients to recurrent VF in hemodynamically unstable patients. Furthermore, ES can occur in the setting of acute reversible factors and/or underlying advanced structural heart disease. This wide clinical spectrum leads to major implications in ES management. Although several studies have focused on the predictors of ES and associated mortality, especially in the setting of VT ablation, only limited data assessing predictors of mortality following ES, are available. Thus, the purpose of this study was to assess the incidence and predictors of long term mortality following hospitalization in the intensive care unit for ES, in a large retrospective multicentric study.
All patients admitted in ICU between january 2015 and june 2022
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All ventricular arrythmias admitted in ICU -
Exclusion Criteria:
-
Mortality
Time frame: at 5 years
Hospital duration
Time frame: 0 to 30 day follow up
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Sep 2025, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →